Tremfya potential highlighted by industry analyst GlobalData – The Pharma Letter

Industry analyst GlobalData has highlighted research showing the potential of Janssens Tremfya (guselkumab) in the treatment of psoriasis.

Johnson & Johnsons (NYSE: JNJ) biotech subsidiary has recently released new data on the interleukin (IL)-23-targeting antibody in adults with moderate-to-severe plaque psoriasis (PsO).

A real-world data analysis and the results of J&Js Phase III VOYAGE 2 study suggest the product could

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Read more here:
Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter